by T cell stimulation was measured by the release of IFN- to the culture medium. exhibit a characteristic TCR-like binding specificity to each Lemildipine of the three gp100-derived epitopes, yet unlike TCRs, they did so with an affinity in the nanomolar range. These TCR-like antibodies identify the native MHCpeptide complex expressed on the surface of antigen-presenting cells. Moreover, they can detect the specific MHCpeptide complexes on the surface of melanoma tumor cells. These results demonstrate the ability to isolate IDH2 high-affinity human recombinant antibodies with the antigen-specific, MHC-restricted specificity of T cells, and this ability was exhibited for three different epitopes of the same melanoma-derived antigen. In recent years, major improvements in tumor immunology have led to an increased understanding of the immune responses against tumors. Especially with melanoma, it is now well established that human melanoma and other tumor cells express antigens that are recognized by cytotoxic T lymphocytes (CTLs) derived from malignancy patients (13). The cascade of molecular acknowledgement events associated with these tumor-associated immune responses entails the expression of specific peptides in complex with MHC class I molecules around the malignancy cells (13). For example, human melanomas express tumor-associated peptides that are offered to the immune system in a complex with class I HLA-A2 molecules (4,5). Although there is usually strong experimental evidence demonstrating the presence of these antigens on a variety of tumors, they are apparently unable to elicit a strong enough anti-tumor immune response Lemildipine (6). Therefore, many modern malignancy immunotherapy approaches are now designed to induce and enhance T cell reactivity against these tumor antigens (711). Tumor-specific MHCpeptide complexes present on the surface of tumor cells may also offer a unique and specific target for an antibody-based therapeutic approach. To develop such a strategy, targeting moieties such as recombinant antibodies that will specifically identify peptideMHC complexes must be isolated. The recent introduction of MHCpeptide tetramers has provided a new tool for studying antigen-specific T cell populations in health and disease, even when they are very rare, by monitoring tetramerT cell binding by means of circulation cytometry (1214). However, to date, there are very few tools available to detect, visualize, count, and study antigen (MHCpeptide) presentation. Indeed, Lemildipine several studies demonstrated that the inability of the patient’s immune system to elicit an effective immune response against the tumor is usually often due to poor antigen presentation (8,9). Antibodies with T cell antigen receptor (TCR)-like specificity could enable measuring the antigen presentation capabilities of such tumor- or antigen-presenting cells (APCs)for example, by direct visualization of the specific MHCpeptide complex around the cell surface. Attempts to use recombinant soluble TCRs for this purpose have largely failed because of their inherent low affinity for their target as well as their instability as recombinant-engineered molecules (15). Therefore, TCR-like antibodies would serve as a valuable tool Lemildipine to obtain precise information about the presence, expression pattern, and distribution of the MHCpeptide complex, around the tumor cell surface, on tumor metastases, in lymphoid organs, and on professional APCs. Antibodies that specifically identify class I MHCpeptide complexes have already been used in murine systems to study antigen presentation, to localize and quantify APCs displaying a T cell epitope, or as a targeting tool (1625). Here, we have isolated a large panel of high-affinity human recombinant Fab antibodies endowed with the antigen-specific, MHC-restricted specificity of T cells. These antibodies identify three common HLA-A2-restricted epitopes of the human melanoma differentiation antigen gp100. We show that this panel of antibodies recognizes HLA-A2 molecules only when displaying the specific peptide against which they were selected; they do not bind HLA-A2 molecules complexed with other gp100-derived epitopes or with other HLA-A2-restricted control peptides. Hence, they exhibit a TCR-like restriction. Moreover, these antibodies have been used to directly visualize the specific HLA-A2/gp100 epitopes on APCs as well as on the surface of Lemildipine melanoma tumor cells by circulation cytometry. == Materials and Methods == == Production of Biotinylated scMHCPeptide Complexes..
